Senthil K Muthuswamy

Chief

National Cancer Institute
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Purpose: Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options. We compared the efficacy of comprehensive precision medicine against that of the conventional treatment in PDAC. Patients and Methods: We report a phase III trial of advanced PDAC in which patients were randomized (1:2) to a conventional treatment treated at physician’s discretion (arm A) or to precision medicine (arm B). Subjects randomized to arm B underwent a tumor biopsy for whole-exome sequencing and to generate avatar mouse models and patient-derived organoids for phenotypic drug screening, with final treatment recommended by the molecular tumor board. The primary objective was median overall survival (OS). Results: A total of 137 patients were enrolled with 125 randomized, 44 to arm A and 81 to arm B. Whole-exome sequencing was performed in 80.3% (65/81) patients of arm B, with potentially actionable mutations detected in 21.5% (14/65). Experimental models were generated in 16/81 patients (19.8%). Second-line treatment was administered to 39 patients in the experimental arm, but only four (10.2%) received personalized treatment, whereas 35 could not receive matched therapy because of rapid clinical deterioration, delays in obtaining study results, or the absence of actionable targets. The median OS was 8.7 and 8.6 months ( P = 0.849) and the median progression-free survival was 3.8 and 4.3 months ( P = 0.563) for the conventional and experimental arms, respectively. Notably, the four patients who received personalized treatment had a median OS of 19.3 months. Conclusions: Personalized medicine was challenging to implement in most patients with PDAC, limiting the interpretation of intention-to-treat analysis. Survival was improved in the subset of patients who did receive matched therapy.

Year:

2025

Ductal and acinar pancreatic organoids are promising models for the study of pancreatic diseases. Genome sequencing studies have revealed that mutations in a G-protein ( GNAS R201C ) are exclusively observed in intraductal papillary mucinous neoplasms (IPMN). The biological mechanisms by which GNAS R201C affects the ductal and acinar exocrine pancreas are unclear. Here, we use human stem-cell-derived pancreatic ductal and acinar organoids and demonstrate that GNAS R201C was more effective in inducing proliferation in ductal organoids compared with acinar organoids. Surprisingly, GNAS R201C -induced cell proliferation was protein kinase A (PKA)-independent in ductal organoids and an immortalized ductal epithelial cell line. Co-expression of oncogenic KRASG12V and GNAS R201C retained PKA-independence in ductal organoids to stimulate cell proliferation. Thus, we identify cell lineage-specific roles for PKA signaling in GNAS R201C -driven cell proliferation in precancerous lesions and report the development of a human pancreatic ductal organoid model system to investigate mechanisms regulating GNAS R201C -induced IPMNs. Implications: The study identifies an opportunity to discover a PKA-independent pathway downstream of oncogene GNAS for managing IPMN lesions and their progression to PDAC.

Year:

2024

Ductal and acinar pancreatic organoids are promising models for the study of pancreatic diseases. Genome sequencing studies have revealed that mutations in a G-protein ( GNAS R201C ) are exclusively observed in intraductal papillary mucinous neoplasms (IPMN). The biological mechanisms by which GNAS R201C affects the ductal and acinar exocrine pancreas are unclear. Here, we use human stem-cell-derived pancreatic ductal and acinar organoids and demonstrate that GNAS R201C was more effective in inducing proliferation in ductal organoids compared with acinar organoids. Surprisingly, GNAS R201C -induced cell proliferation was protein kinase A (PKA)-independent in ductal organoids and an immortalized ductal epithelial cell line. Co-expression of oncogenic KRASG12V and GNAS R201C retained PKA-independence in ductal organoids to stimulate cell proliferation. Thus, we identify cell lineage-specific roles for PKA signaling in GNAS R201C -driven cell proliferation in precancerous lesions and report the development of a human pancreatic ductal organoid model system to investigate mechanisms regulating GNAS R201C -induced IPMNs. Implications: The study identifies an opportunity to discover a PKA-independent pathway downstream of oncogene GNAS for managing IPMN lesions and their progression to PDAC.

Year:

2024

Ductal and acinar pancreatic organoids are promising models for the study of pancreatic diseases. Genome sequencing studies have revealed that mutations in a G-protein (GNASR201C) are exclusively observed in intraductal papillary mucinous neoplasms (IPMN). The biological mechanisms by which GNASR201C affects the ductal and acinar exocrine pancreas are unclear. Here, we use human stem-cell-derived pancreatic ductal and acinar organoids and demonstrate that GNASR201C was more effective in inducing proliferation in ductal organoids compared with acinar organoids. Surprisingly, GNASR201C-induced cell proliferation was protein kinase A (PKA)-independent in ductal organoids and an immortalized ductal epithelial cell line. Co-expression of oncogenic KRASG12V and GNASR201C retained PKA-independence in ductal organoids to stimulate cell proliferation. Thus, we identify cell lineage-specific roles for PKA signaling in GNASR201C-driven cell proliferation in precancerous lesions and report the development of a human pancreatic ductal organoid model system to investigate mechanisms regulating GNASR201C-induced IPMNs. Implications: The study identifies an opportunity to discover a PKA-independent pathway downstream of oncogene GNAS for managing IPMN lesions and their progression to PDAC.

Year:

2024

Collaborators (7)

Pedro P Lopez-Casas

Profesor

Universidad Francisco de Vitoria

SPAIN
View details

Ling Huang

Assistant Professor

Michigan State University

UNITED STATES
View details

Rocio Garcia-Carbonero

Profesor Titular

Universidad Complutense de Madrid Facultad de Medicina

SPAIN
View details

Manuel Hidalgo

Professor

NYU Langone Health

UNITED STATES
View details

Bruno Bockorny

Beth Israel Deaconess Medical Center

UNITED STATES
View details

Carmen Guerra

"Científico Titular " (On leave of absence)

CSIC

SPAIN
View details

Raul S. Gonzalez

Emory University Hospital

UNITED STATES
View details